Logo
x

Search

Subscribe Now

SpringWorks

SpringWorks Published P-III Trial (DeFi) Results of Nirogacestat for Desmoid Tumors in the NEJM

SpringWorks Published P-III Trial (DeFi) Results of Nirogacestat for Desmoid Tumors in the NEJM

  • March 9, 2023
SpringWorks Reports the Completion of NDA Submission to the US FDA for Nirogacestat to Treat Desmoid Tumors

SpringWorks Reports the Completion of NDA Submission to the US FDA for Nirogacestat to Treat Desmoid Tumors

  • December 28, 2022
SpringWorks Entered into an Expanded Non-Exclusive License Agreement with GSK for Nirogacestat + Blenrep to Treat Multiple Myeloma

SpringWorks Entered into an Expanded Non-Exclusive License Agreement with GSK for Nirogacestat + Blenrep to Treat Multiple Myeloma

  • September 9, 2022
SpringWorks Entered into a Clinical Trial Collaboration and Supply Agreement with Regeneron to Evaluate Nirogacestat + REGN5458 for Multiple Myeloma

SpringWorks Entered into a Clinical Trial Collaboration and Supply Agreement with Regeneron to Evaluate Nirogacestat + REGN5458 fo...

  • April 20, 2022
SpringWorks Completes an Enrollment of Mirdametinib in P-IIb ReNeu Trial for the Treatment of NF1-Associated Plexiform Neurofibromas

SpringWorks Completes an Enrollment of Mirdametinib in P-IIb ReNeu Trial for the Treatment of NF1-Associated Plexiform Neurofibrom...

  • November 29, 2021
PharmaShots Weekly Snapshots (October 18 - 22, 2021)

PharmaShots Weekly Snapshots (October 18 - 22, 2021)

  • October 22, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.